Boston Scientific Co. (NYSE:BSX) Shares Sold by Crystal Rock Capital Management

Crystal Rock Capital Management cut its holdings in Boston Scientific Co. (NYSE:BSX) by 4.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 94,875 shares of the medical equipment provider’s stock after selling 4,500 shares during the period. Boston Scientific makes up approximately 3.6% of Crystal Rock Capital Management’s investment portfolio, making the stock its 10th largest position. Crystal Rock Capital Management’s holdings in Boston Scientific were worth $5,485,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Victory Capital Management Inc. grew its holdings in shares of Boston Scientific by 5.6% during the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock worth $27,353,000 after purchasing an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Boston Scientific during the fourth quarter valued at approximately $5,116,000. Glenmede Trust Co. NA boosted its holdings in shares of Boston Scientific by 12.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock valued at $551,000 after purchasing an additional 1,123 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Boston Scientific by 2.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after purchasing an additional 38,249 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new position in shares of Boston Scientific during the 4th quarter worth $3,746,000. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The disclosure for this sale can be found here. Insiders sold 60,797 shares of company stock worth $4,138,090 over the last three months. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on BSX shares. Mizuho lifted their target price on Boston Scientific from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. UBS Group increased their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada upped their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. Oppenheimer raised their price objective on Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. upped their target price on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $75.09.

Boston Scientific Price Performance

Boston Scientific stock traded up $0.34 during midday trading on Wednesday, reaching $72.21. 5,438,466 shares of the stock were exchanged, compared to its average volume of 6,634,021. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The firm has a market cap of $108.32 billion, a PE ratio of 60.39, a PEG ratio of 2.49 and a beta of 0.78. The company’s fifty day moving average is $68.07 and its 200-day moving average is $60.95. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same quarter in the previous year, the firm posted $0.45 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.